Rédaction Africa Links 24 with Damian Garde
Published on 2024-03-27 13:25:58
A new biotech newsletter is set to launch tomorrow, and you don’t want to miss out on the latest updates and developments in the industry. Damian is here to provide you with details on a potentially major drug approval, an idea to make CAR-T more equitable, and the slow launch of a gene therapy.
Blackstone Life Sciences has announced that they will be investing up to $750 million to support Moderna’s mRNA-based flu vaccine programs. This partnership aims to boost the development of innovative vaccines to combat influenza.
However, not all news is positive in the biotech industry. The European academic “TUDCA” study in ALS failed to meet its primary goal of slowing disease progression. This study was designed to investigate one of the two drug ingredients in Amylyx Pharma’s Relyvrio, which also recently faced failure in its clinical trial.
Merck, on the other hand, received FDA approval for a new treatment for a rare cardiovascular disease. The drug, Winrevair, is expected to generate significant revenue for the company, as analysts predict it could bring in nearly $5 billion a year at its peak. Despite some concerns about side effects, the FDA decided not to add a boxed warning to the drug’s label.
Bluebird Bio’s gene therapy for sickle cell disease, Lyfgenia, has faced a slow start since receiving FDA approval. Despite the approval, no patients have received treatment yet. The company has stated that the first dosing is imminent, but the delay has caused some concerns among investors and analysts.
In other news, the Brazilian government is taking steps to make CAR-T therapies more affordable. By partnering with a U.S. nonprofit called Caring Cross, the government aims to reduce the cost of CAR-T treatments dramatically. This initiative could pave the way for cheaper CAR-T treatments in Latin America and beyond.
Adam Feuerstein, a reputable biotech reporter, is launching a new subscriber-only newsletter called Adam’s Biotech Scorecard. This newsletter promises to offer candid analysis of the latest news and events in the biotech and finance sectors from an experienced perspective.
As the biotech industry continues to evolve, it’s crucial to stay informed about the latest developments and trends. Keep an eye out for the new biotech newsletter launching tomorrow to ensure you don’t miss out on important updates that could impact the industry. Subscribe today to stay ahead of the curve and be in the know about all things biotech.
